<DOC>
	<DOC>NCT02655757</DOC>
	<brief_summary>This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on Progression of Coronary Intermediate Lesion.</brief_summary>
	<brief_title>Effect of Sitagliptin on Progression of Coronary Intermediate Lesion</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients &gt; 18, &lt; 80 years old, with type 2 diabetes mellitus and angiographically proven Coronary Intermediate Lesion. Allergy or hypersensitivity to any of the drug's components. Severe liver failure, moderate or severe kidney failure Malignant disease. Active infectious disease. Pregnancy or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>